Value Proposition:
• A broadly protective vaccine against HPV.
• Can be delivered without needles.
• Can be chemically synthesized at low cost.
Technical Details:
Human papillomavirus (HPV) infections are the most common sexually transmitted infection in the United States. Infection by over 15 different oncogenic HPV genotypes is a cause of cervical cancer. Therefore, a low-cost, broadly protective vaccine that can be delivered without needles is urgently needed. JHU scientists have discovered a novel lipopeptide derived from the minor capsid protein L2 of medically-significant HPV genotype and produced by direct synthesis as an approach to generate broadly protective vaccines against HPV-related disease. The L2 lipopeptide can be chemically synthesized at low cost. It can be delivered intranasally without the use of needles.
Looking for Partners:
A broadly protective vaccine against Human papillomavirus infection and any of its sequelae.
